Incyte Corporation INCY

123.20 (1.62) (1.30%) as of 29 Sep
Market cap
$26.1B
P/E
15.4×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Incyte Corporation (INCY) EV/Sales

As of 28 September 2026, Incyte Corporation (INCY) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.9× (April 2025) to 36.5× (September 2015); the current reading is higher than 28% of that period. That is below the Biotechnology industry median of 10.8× and in line with the Healthcare sector median of 3.6×.

EV/Sales, daily

Annual

Period EV/Sales Change
FY2025 3.1× 6.51%
FY2024 2.9× (3.60%)
FY2023 3.0× (30.02%)
FY2022 4.3× (8.31%)
FY2021 4.6× (28.02%)
FY2020 6.5× (16.55%)
FY2019 7.7× 20.38%
FY2018 6.4× (49.36%)
FY2017 12.7× (26.41%)
FY2016 17.2× (32.97%)

Quarterly

Period EV/Sales Change
Jun 2026 3.1× 13.50%
Mar 2026 2.8× (9.91%)
Dec 2025 3.1× 7.51%
Sep 2025 2.8× 20.55%
42 more quarters

Against its own ten years

Low 1.9× High 36.5×
Ten-year median 6.6×
Current reading's percentile 28

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on INCY